 Another weakness of former studies was the use of first-generation drug eluting stent DES showing an increased risk of restenosis and late and very late stent thrombosis. Many randomized studies documented superiority of new generation DES, with more biocompatible or bioresorbable polymer in terms of the incidence of MACE SPIRIT, LEADERS. Recently, fully bioresorbable vascular scaffolds BVS have been introduced into routine clinical practice. Preliminary results of the ABSORB EXTEND trial demonstrated similar efficacy and safety of the Absorb BVS, as compared with the best-in-class its metallic counterpart XIENCE. Since the complete resorption of the scaffold requires two-three years, the greatest clinical benefit will be observed a couple of years after implantation. Total bioresorption of the scaffold not only allows to restore the physiological function of the vessel, but also eliminates a number of adverse events associated with the presence of permanent metallic prosthesis in the vessel wall, such as very late stent thrombosis and the neo-atherosclerosis development. 